DK1334174T3 - Paramyxovirusvektor til genoverförsel til det cardiovaskulære system - Google Patents

Paramyxovirusvektor til genoverförsel til det cardiovaskulære system

Info

Publication number
DK1334174T3
DK1334174T3 DK01981031T DK01981031T DK1334174T3 DK 1334174 T3 DK1334174 T3 DK 1334174T3 DK 01981031 T DK01981031 T DK 01981031T DK 01981031 T DK01981031 T DK 01981031T DK 1334174 T3 DK1334174 T3 DK 1334174T3
Authority
DK
Denmark
Prior art keywords
cardiovascular system
vector
gene transfer
paramyxovirus vector
paramyxovirus
Prior art date
Application number
DK01981031T
Other languages
English (en)
Inventor
Mamoru Hasegawa
Uta Griesenbach
Stefano Ferrari
Duncan M Geddes
Eric Wfw Alton
Xiaogang Hou
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Application granted granted Critical
Publication of DK1334174T3 publication Critical patent/DK1334174T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01981031T 2000-11-08 2001-11-08 Paramyxovirusvektor til genoverförsel til det cardiovaskulære system DK1334174T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000339942A JP2002142770A (ja) 2000-11-08 2000-11-08 循環系への遺伝子送達用パラミクソウイルスベクター

Publications (1)

Publication Number Publication Date
DK1334174T3 true DK1334174T3 (da) 2006-06-26

Family

ID=18814933

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01981031T DK1334174T3 (da) 2000-11-08 2001-11-08 Paramyxovirusvektor til genoverförsel til det cardiovaskulære system

Country Status (13)

Country Link
US (1) US20040101965A1 (da)
EP (2) EP1334174B1 (da)
JP (1) JP2002142770A (da)
KR (1) KR100852078B1 (da)
CN (1) CN1555417B (da)
AT (1) ATE323149T1 (da)
AU (1) AU2002212733A1 (da)
CA (1) CA2428073C (da)
DE (1) DE60118771T2 (da)
DK (1) DK1334174T3 (da)
ES (1) ES2260301T3 (da)
HK (1) HK1070100A1 (da)
WO (1) WO2002038726A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
CN1367839A (zh) 1999-09-06 2002-09-04 株式会社载体研究所 含有已改变的转录起始序列的副粘病毒
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
US20020002143A1 (en) 2000-03-30 2002-01-03 Munehide Kano AIDS virus vaccines using sendai virus vector
CA2413995C (en) * 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
AU2001266337A1 (en) * 2000-06-27 2002-01-08 Dnavec Research Inc. Virus vector for transferring gene into renal cells
JPWO2002031138A1 (ja) * 2000-10-06 2004-02-19 株式会社ディナベック研究所 骨格筋に外来遺伝子を導入するためのパラミクソウイルスベクター
ES2305138T3 (es) * 2000-11-27 2008-11-01 Dnavec Research Inc. Vector de paramixovirus que codifica factor 2 de crecimiento de fibroblastos (fgf2) y uso del mismo.
KR20040104673A (ko) * 2002-04-30 2004-12-10 가부시키가이샤 디나벡크 겐큐쇼 헤마글루티닌 활성을 저하시킨 약제 또는 유전자 운반 조성물
CA2497475A1 (en) * 2002-09-04 2004-03-18 Dnavec Research Inc. Methods of producing a viral vector comprising a membrane protein that binds to sialic acid as a component of the envelope using neuraminidase derived from gram-positive bacteria
US20060104950A1 (en) * 2002-10-24 2006-05-18 Shinji Okano Methods of Tranducing genes into T cells
CN1816618A (zh) * 2003-06-30 2006-08-09 株式会社载体研究所 携带具有改变的高变区的基因的负链rna病毒载体
EP1712243A4 (en) * 2004-01-13 2007-04-11 Dnavec Research Inc GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE
WO2005071085A1 (ja) * 2004-01-22 2005-08-04 Dnavec Research Inc. ウイルスベクターの製造方法
JPWO2005097988A1 (ja) * 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
AU2006237903A1 (en) * 2005-04-20 2006-10-26 Dna Vec Corporation Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease
EP1916298B1 (en) * 2005-06-14 2011-12-28 Dnavec Corporation Methods for producing monoclonal antibodies
WO2007049752A1 (ja) 2005-10-28 2007-05-03 Dnavec Corporation Rnaウイルスまたはdnaウイルスのスパイクタンパク質でシュードタイプ化したレンチウイルスベクターを用いた気道上皮幹細胞への遺伝子導入
CA2636600A1 (en) * 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
CN106913865A (zh) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
JPS6147185A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147186A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6562596B1 (en) * 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
PT702085E (pt) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
ATE298789T1 (de) * 1995-10-31 2005-07-15 Dnavec Research Inc Negativstrand rna virus mit selbständiger replikationsaktivität
ATE470704T1 (de) * 1995-11-01 2010-06-15 Dnavec Research Inc Rekombinantes sendai-virus
EP0884383A4 (en) 1996-02-29 2001-12-05 Takara Shuzo Co METHOD FOR CLEANING AND REMOVING VIRUSES.
US5833651A (en) * 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
EP0953647B1 (en) * 1996-12-16 2008-05-28 Eisai R&D Management Co., Ltd. Method for preparing retrovirus vector for gene therapy
CA2205076A1 (en) * 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
FR2766706B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
US5962274A (en) * 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
EP1013667B1 (en) * 1998-11-09 2006-10-11 Nippon Biologicals, Inc. Process for preparation of cytokine using a sendai virus expression system
JP2000201689A (ja) * 1998-11-09 2000-07-25 Nippon Bio Capital Limited:Kk センダイウイルス発現系を用いたサイトカインの製造方法
JP2000253876A (ja) * 1999-03-08 2000-09-19 Dnavec Research Inc センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
ATE367445T1 (de) 1999-05-18 2007-08-15 Dnavec Research Inc Viraler paramyxoviridae vektor mit einem defekten hüllprotein-gen
JP3766596B2 (ja) 1999-05-18 2006-04-12 株式会社ディナベック研究所 パラミクソウイルスに由来するｒｎｐ
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
CN1367839A (zh) * 1999-09-06 2002-09-04 株式会社载体研究所 含有已改变的转录起始序列的副粘病毒
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
US20030170210A1 (en) * 2000-01-19 2003-09-11 Ichiro Masaki Use of paramyxovirus vector in gene transfer into blood vessel
US20020002143A1 (en) * 2000-03-30 2002-01-03 Munehide Kano AIDS virus vaccines using sendai virus vector
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
CA2413995C (en) * 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
AU2001266337A1 (en) * 2000-06-27 2002-01-08 Dnavec Research Inc. Virus vector for transferring gene into renal cells
JPWO2002031138A1 (ja) * 2000-10-06 2004-02-19 株式会社ディナベック研究所 骨格筋に外来遺伝子を導入するためのパラミクソウイルスベクター
ES2305138T3 (es) * 2000-11-27 2008-11-01 Dnavec Research Inc. Vector de paramixovirus que codifica factor 2 de crecimiento de fibroblastos (fgf2) y uso del mismo.
US20060104950A1 (en) * 2002-10-24 2006-05-18 Shinji Okano Methods of Tranducing genes into T cells
CN1768145A (zh) * 2003-01-31 2006-05-03 株式会社载体研究所 编码核酶的副粘病毒载体及其应用
CN1816618A (zh) * 2003-06-30 2006-08-09 株式会社载体研究所 携带具有改变的高变区的基因的负链rna病毒载体
US20070269414A1 (en) * 2003-11-04 2007-11-22 Shinji Okano Method for Producing Gene Transferred Denritic Cells
EP1712243A4 (en) * 2004-01-13 2007-04-11 Dnavec Research Inc GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE
JPWO2005097988A1 (ja) * 2004-03-23 2008-02-28 株式会社ディナベック研究所 組織の維持および／または修復に関連する骨髄関連細胞
AU2006237903A1 (en) * 2005-04-20 2006-10-26 Dna Vec Corporation Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease

Also Published As

Publication number Publication date
HK1070100A1 (en) 2005-06-10
AU2002212733A1 (en) 2002-05-21
CN1555417A (zh) 2004-12-15
WO2002038726A3 (en) 2003-03-20
EP1334174A2 (en) 2003-08-13
EP1662003A2 (en) 2006-05-31
DE60118771T2 (de) 2007-04-12
KR20030074617A (ko) 2003-09-19
CA2428073C (en) 2012-01-10
ATE323149T1 (de) 2006-04-15
CA2428073A1 (en) 2002-05-16
CN1555417B (zh) 2010-04-28
US20040101965A1 (en) 2004-05-27
ES2260301T3 (es) 2006-11-01
JP2002142770A (ja) 2002-05-21
KR100852078B1 (ko) 2008-08-13
EP1662003A3 (en) 2006-06-14
WO2002038726A2 (en) 2002-05-16
DE60118771D1 (de) 2006-05-24
EP1334174B1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
DK1334174T3 (da) Paramyxovirusvektor til genoverförsel til det cardiovaskulære system
NO973745L (no) Nukleinsyreholdig preparat, dets fremstilling og anvendelse
PL346212A1 (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
CY1107488T1 (el) Σταθερα ξηραμενα δια ψεκασμου πρωτεϊνικα σκευασματα
IT1317034B1 (it) Metodo di estrazione di prodotti ad attivita' farmaceutica da piantespermatofite, prodotti cosi' ottenuti e loro impiego in medicina, in
CA2185712A1 (en) Enhanced virus-mediated dna transfer
DE60001492D1 (de) Pharmazeutische aerosolformulierung
ATE492638T1 (de) Vektorkonstruktionen
DE69333529D1 (de) Pflanzenvirus-vektor, plasmid, methode der expression fremder gene und methode zur gewinnung obiger genprodukte
GB0103301D0 (en) Culture of crypthecodinium cohnii and microorganisms derived therefrom
HRP20050424A2 (en) Process for making risperidone and intermediates thereof
ATE422534T1 (de) Verfahren zum trocknen von mikroorganismen
NO20051683L (no) Intermediater ved fremstilling av fenoksyeddiksyrederivater samt fremgangsmate ved anvendelse av samme
ITRM980716A1 (it) Atomizzatore rotativo per applicare rivestimenti su oggetti, fornito di un sistema ad aria per la distribuzione del getto.
DE69434173D1 (de) Herstellung von trehalose in pflanzen
DE50110723D1 (de) Isolierte luziferasen sowie deren verwendung
HUP9701387A2 (hu) Fűszeres mártás
HUP0300727A2 (hu) Nukleinsav-konstrukciók, ezekkel transzformált vaszkuláris sejtek, ezeket a konstrukciókat hasznosító gyógyászati kompozíciók, és eljárások angiogenezis indukálásához
WO2003029274A3 (en) Paramyxoviruses as gene transfer vectors to lung cells
WO2002002766A3 (en) Natural promoters for gene expression and metabolic monitoring in bacillus species
DK1283868T3 (da) Isoleret gum-operon fra Xyllela fastidiosa, isolerede nukleinsyremolekyler derfra og anvendelser deraf
DK0500188T3 (da) Fremgangsmåde til fremstilling af alfa-acetomælkesyre
EP1030867A4 (en) MAMMAL MILK GROWTH FACTOR
BR0003561A (pt) Processo para a preparação fermentativa de produtos metabólicos e para as sequências de nucleotìdeos codificando para o gene sod
ITMI20021394A0 (it) Apparecchiatura di surgelazione particolarmente per prodotti alimentari atta a limitare l'inflitrazione di aria umida nella camera di surgel